Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: Preliminary results of a validation study with clinical experts
K. Bruynesteyn et al., Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: Preliminary results of a validation study with clinical experts, J RHEUMATOL, 28(4), 2001, pp. 904-910
To determine the minimal clinically important difference (MCID) between han
d and foot films with a 1 year interval assessed with the Sharp/van der Hei
jde or Larsen/Scott scoring method. Progression scores of the 2 methods wer
e compared with the opinion of an international expert panel on clinical re
levance of radiological joint damage in 4 predefined clinical settings. The
expert panel consisted of 3 rheumatologists, who evaluated 46 pairs of han
d and foot films, taken with 1 year intervals, of patients with early rheum
atoid arthritis, Receiver operating characteristics curves analyzed the acc
uracy of different threshold values (progression scores) of the 2 scoring m
ethods to detect the presence or absence of clinically important difference
, as defined by the expert panel as external criterion. The threshold value
with the highest accuracy was subsequently chosen as the score representin
g the MCID. Five Sharp/van der Heijde units and 2 Larsen/Scott units were t
he best cutoffs, The accompanying sensitivities ranged from 77% to 100% for
the Sharp/van der Heijde method and from 73% to 84% for the Larsen/Scott m
ethod for the 4 clinical settings, The specificities were between 78% and 8
4% for the Sharp/van der Heijde method and between 74% and 94% for the Lars
en/Scott method. The smallest progression score that can be detected apart
from interobserver measurement error. the smallest detectable difference (S
DD), was equal to or larger than the calculated MCID, 5 Sharp/van der Heijd
e units and 6 Larsen/Scott units in our study, if the mean progression scor
es of the same 2 observers were used. The SDD is a conservative estimate of
the MCID: our panel rated progression at or below this level as clinically
significant.